Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.

The company expects full-year adjusted earnings of $8.53 to $8.65 per share, up from its prior forecast of $8.44 to $8.59 per share.of Harpoon Therapeutics in January. The company develops immune-based cancer drugs. The guidance also includes a negative impact of 30 cents per share from foreign exchange changes.

Excluding acquisition and restructuring costs, Merck earned $2.07 per share for the first quarter. Both adjusted and non-adjusted profit for the period include the charge related to the Harpoon deal.patent expiration Merck is also cutting costs under a new restructuring program it announced in February. Those efforts aim to improve the manufacturing network of both its pharmaceutical division and animal health business.

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and moreThese are the stocks posting the largest moves in premarket trading.
แหล่ง: CNBC - 🏆 12. / 72 อ่านเพิ่มเติม »

Stocks making the biggest moves midday: GameStop, Merck, Carnival, Cintas and moreThese are the stocks posting the largest moves in midday trading.
แหล่ง: CNBC - 🏆 12. / 72 อ่านเพิ่มเติม »

Cramer's week ahead: Earnings from Tesla, Merck and Big TechCNBC’s Jim Cramer said next week’s PCE index report will be the real gauge of inflation.
แหล่ง: NBCLA - 🏆 319. / 59 อ่านเพิ่มเติม »

Cramer’s week ahead: Earnings from Tesla, Merck and Big TechCNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
แหล่ง: CNBC - 🏆 12. / 72 อ่านเพิ่มเติม »